CTOs on the Move

ActaCell

www.actacell.com

 
ActaCell is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.actacell.com
  • 2105 Donley Dr Ste 200
    Austin, TX USA 78758
  • Phone: 512.834.8600

Executives

Name Title Contact Details

Similar Companies

Avitide

Avitide is dedicated to advancing our partners’ clinical pipelines and commercial manufacturing processes with a rapid, exclusive, and enabling affinity purification platform technology.

Exicure

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Fraunhofer Center for Laser Technology

Fraunhofer Center for Laser Technology is a Plymouth, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Uromedica

Uromedica is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BPGbio

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.